SecBot SecBot
8-K ·Filed Nov 2, 2026

KPTI

Karyopharm Therapeutics Inc.
BEARISH
Impact 10/10
Horizonweeks Processed13d 20h ago SEC0001193125-26-444164
8-K material event: Items 1.01, 1.03, 2.04
Actionable Insight ▼ Bearish

Monitor the FDA's decision on the sNDA for XPOVIO in myelofibrosis expected around November 10, 2026, as this will determine the value of the MF CVRs issued to secured creditors. Also watch for any qualified bids exceeding the $335.4M threshold in the court-supervised sale process, which could alter recoveries for creditors.

DirectionBearish
Confidencehigh
Horizonweeks

Omisirge

▼ Bearish Named in this 8-K
Impact
Phase
Approved
Time to market
Already approved and commercialized (FDA approved April 2023 for hematologic malignancies; December 2025 for severe aplastic anemia).
Next catalyst
None dated

What to watchOmisirge is already FDA-approved with no pending regulatory binary for this drug. The key event for KPTI holders is the Chapter 11 court-supervised sale process (confirmation hearing January 11, 2027) and the proposed merger with Ayrmid closing in Q1 2027, but existing KPTI equity is expected to receive zero recovery.

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.0883
T+0 close · Nov 2, 2026 · via day close
Latest settled
−17.44%
T+1 · $0.0729 · next T+5 due 7d ago
Vs SPY
−19.09%
α at T+1
Latest observation
−56.45%
T+4 · FF3 residual α
  1. T+0 · Nov 3 $0.0883entry
  2. T+1 · 13d ago −17.44%α −19.09% · $0.0729
  3. T+5 · due 7d ago Pending
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Karyopharm Therapeutics filed a prepackaged Chapter 11 bankruptcy on November 2, 2026, supported by 100% of its secured creditors. The plan provides for a reorganization transaction merging the company with Ayrmid Ltd., where secured funded debt claims (~$276M) will be exchanged for 55% of NewCo common stock and contingent value rights tied to myelofibrosis sales. Existing common and preferred equity will be canceled with no recovery. A court-supervised sale process continues with a $335.4M minimum bid threshold. The company had $8.1M cash at filing against ~$390M in total funded debt obligations.

Key Financial Metrics

Deal Type
merger

Key Facts

  • Filed prepackaged Chapter 11 on November 2, 2026 in the Southern District of Texas
  • Total funded debt obligations of approximately $390M: $146M 1L Term Loan, $16M 1.5L 2028 Notes, $114M 2L 2029 Notes, $114M RIFA
  • Company had $8.1M cash, cash equivalents, and investments as of the Petition Date
  • Existing common stock and preferred equity interests will be canceled with zero recovery
  • Secured funded debt claims (~$276M aggregate) to be exchanged for 55% of NewCo common stock plus myelofibrosis contingent value rights
  • Ayrmid equityholders receive 45% of NewCo common stock plus Omisirge contingent equity
  • DIP facility of $55M new-money senior secured financing committed by existing 1L lenders
  • NewCo exit facility of up to $135M to repay DIP new-money claims and fund working capital
  • RIFA claims ($113.5M) exchanged for unsecured 3.0% royalty on selinexor net revenues for 5 years with $18.75M liquidated damages provision
  • Sale alternative requires minimum net proceeds of $335.4M at closing
  • Phase 3 SENTRY trial met spleen volume endpoint but missed symptom score endpoint; sNDA for myelofibrosis filed August 31, 2026 with FDA decision expected ~November 10, 2026
  • Phase 3 XPORT-EC-042 trial in endometrial cancer failed primary endpoint on July 30, 2026
  • Company reported loss from operations of ~$49.3M for six months ended June 30, 2026
  • Accumulated deficit of approximately $1.8B as of June 30, 2026
  • Total revenue was $146.1M in 2025 including $114.9M U.S. XPOVIO net product revenue
  • Voting deadline for impaired creditor classes is November 30, 2026; confirmation hearing scheduled January 11, 2027
  • Nasdaq delisting expected; NewCo will emerge as a private company

Financial Impact

Total funded debt of ~$390M; secured creditors receive equity in NewCo; existing equity holders receive nothing; DIP facility of $55M; NewCo exit facility up to $135M

debtequitydilutionrevenue

Risk Factors

  • FDA may not accept or approve the sNDA for myelofibrosis, rendering MF CVRs worthless
  • Sale process may not yield a qualified bid meeting the $335.4M minimum threshold
  • Merger with Ayrmid may not close due to regulatory or financing conditions
  • NewCo exit facility of up to $135M may not be available on contemplated terms
  • Integration risks combining Karyopharm and Ayrmid businesses
  • Existing equity holders receive no recovery; common stock will be canceled and delisted
  • document contains text addressed to automated readers

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-444164
Document: d141618dex101.htm0001193125-26-444164

Track record

30 reports on KPTI

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +97.24% at T+60 after the Aug 13, 2026 report. 12 of 13 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.0102 Now $0.0290 +184.31% settles Feb 12
  2. Nov 13, 20263d ago NT 10-Q Bearish 7/10 Entry $0.0102 Now $0.0290 −184.31% settles Feb 12
  3. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $0.0260 Now $0.0290 +11.54% settles Feb 10
  4. Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $0.0400 Now $0.0290 −27.50% settles Feb 5
  5. Nov 5, 202611d ago 8-K Bearish 8/10 Entry $0.0601 Now $0.0290 +51.75% settles Feb 3
  6. Nov 2, 202614d ago 8-K Bearish 10/10 Viewing Entry $0.0883 Now $0.0290 +67.16% settles Feb 1
  7. Nov 2, 202614d ago 8-K Bearish 7/10 Entry $0.1120 Now $0.0290 +74.11% settles Jan 29
  8. Oct 28, 202619d ago SC 13G/A Bearish 5/10 Entry $0.8798 Now $0.0290 +96.70% settles Jan 27
  9. Oct 22, 202625d ago 8-K Bearish 6/10 Entry $0.5175 Now $0.0290 +94.40% settles Jan 21
  10. Oct 14, 20264w ago 8-K Neutral 3/10 Entry $0.3150 Now $0.0290 −90.79% settles Jan 11
Showing 10 of 30

US Market Status

Market Closed · Opens in 6h 58m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026